The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Updates: DPd treatment in patients with R/R myeloma
Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, highlights recent advances in treatment options for multiple myeloma. In this video, Dr Kaufman briefly describes the efficacy of daratumumab, pomalidomide and dexamethasone (DPd) combination in patients with relapsed and/or refractory (R/R) multiple myeloma. Following this, Dr Kaufman explains the results from a retrospective analysis investigating the efficacy of DPd treatment in patients treated at first relapse following lenalidomide maintenance. Dr Kaufman draws focus on the impressive rate of progression-free survival (PFS), as well as the long-term benefits seen in these patients. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
